Literature DB >> 21565901

'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought.

Sarah Hewlett1, Tessa Sanderson, James May, Rieke Alten, Clifton O Bingham, Marita Cross, Lyn March, Christof Pohl, Thasia Woodworth, Susan J Bartlett.   

Abstract

OBJECTIVE: People with RA have episodes of worsening disease activity (flares) that prompt them to seek clinical review or medication change. This study explored patients' perspectives of flare that prompts them to seek medication review.
METHODS: Fourteen focus groups across five countries comprised 67 RA patients. Transcripts were analysed by several researchers and a patient, using inductive thematic analysis.
RESULTS: Patients use flare for five different scenarios, including flare that prompts medical help-seeking, where six themes were identified. In 'Symptoms and early warnings', pain is intense (wanting to die), constant and persistent and considered a key feature. Systemic features predominate, including fatigue, feeling generally ill (flu-like), physical and cognitive shut-down and social withdrawal. Warning signs (prodrome) comprise fatigue and flu-like symptoms. 'Self-management of intensifying symptoms' includes pacing, heat/cold, rest and increasing medication, often without medical advice. Patients 'Define this as uncontrollable flare' when clusters of unprovoked, persistent symptoms halt their ability to run daily life, until prompted into 'Seeking help when symptoms can't be contained'. Underpinning themes are 'Individual context' (e.g. different symptom clusters) and 'Uncertainty' (e.g. when to seek help). Patients report that the current patient global visual analogue scale (VAS) does not capture flare.
CONCLUSION: Patients use flare for multiple events and seek help for complex clusterings of intense, unprovoked symptoms that defy self-management, not necessarily captured in joint counts or global VAS. Flare terminology and definition have implications for clinical practice and trials, therefore further research should establish a professional/patient consensus.

Entities:  

Mesh:

Year:  2011        PMID: 21565901     DOI: 10.1093/rheumatology/keq455

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  52 in total

Review 1.  More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions.

Authors:  Ana-Maria Orbai; Serena Halls; Sarah Hewlett; Susan J Bartlett; Amye L Leong; Clifton O Bingham
Journal:  J Rheumatol       Date:  2015-03-01       Impact factor: 4.666

2.  Updating the OMERACT filter: core areas as a basis for defining core outcome sets.

Authors:  John R Kirwan; Maarten Boers; Sarah Hewlett; Dorcas Beaton; Clifton O Bingham; Ernest Choy; Philip G Conaghan; Maria-Antonietta D'Agostino; Maxime Dougados; Daniel E Furst; Francis Guillemin; Laure Gossec; Désirée M van der Heijde; Margreet Kloppenburg; Tore K Kvien; Robert B M Landewé; Sarah L Mackie; Eric L Matteson; Philip J Mease; Peter A Merkel; Mikkel Ostergaard; Lesley Ann Saketkoo; Lee Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell
Journal:  J Rheumatol       Date:  2014-03-15       Impact factor: 4.666

Review 3.  Patient reported outcomes in rheumatoid arthritis clinical trials.

Authors:  Ana-Maria Orbai; Clifton O Bingham
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 4.  Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.

Authors:  Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz
Journal:  Nat Rev Rheumatol       Date:  2018-01-11       Impact factor: 20.543

5.  Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Authors:  Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham
Journal:  J Rheumatol       Date:  2017-08-15       Impact factor: 4.666

6.  Experiences of gout-related disability from the patients' perspective: a mixed methods study.

Authors:  Peter M ten Klooster; Harald E Vonkeman; Martijn A H Oude Voshaar; Christina Bode; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-08       Impact factor: 2.980

7.  Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.

Authors:  Suz Jack Chan; Lisa K Stamp; Nicola Liebergreen; Henry Ndukwe; Carlo Marra; Gareth J Treharne
Journal:  Patient       Date:  2020-04       Impact factor: 3.883

Review 8.  Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop.

Authors:  Vivian P Bykerk; Elisabeth Lie; Susan J Bartlett; Rieke Alten; Annelies Boonen; Robin Christensen; Daniel E Furst; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; James E May; Pam Montie; Ana-Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia Woodworth; Clifton O Bingham; Ernest H Choy
Journal:  J Rheumatol       Date:  2014-03-01       Impact factor: 4.666

Review 9.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 10.  Non-inflammatory Causes of Pain in Patients with Rheumatoid Arthritis.

Authors:  Sean D Boyden; Imtiyaz N Hossain; Alyssa Wohlfahrt; Yvonne C Lee
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.